Wes Streeting Criticises Drug Firms: Pricing Offer Rejection

Here’s a summary of the news article:

The UK government and the pharmaceutical industry (represented by the⁣ ABPI) have reached⁤ a standoff over a voluntary scheme to control NHS drug costs.

The Scheme: the scheme caps NHS ⁤spending on branded medicines,with companies paying back any revenue exceeding that cap.It was ⁢designed to prevent costs from spiraling,but has become more expensive for drug companies than initially anticipated. The Dispute: The government proposed changes to lower payment rates for companies, but the ABPI rejected the offer. The core issue is the rebate rate – currently around 23% (higher than the initially forecast 15%) – and the ‍overall amount companies are expected to pay ‍back (£13.5bn forecast).
Government⁢ Position (Shadow Health Secretary Wes ⁢Streeting): He accuses the industry of being “shortsighted” and unwilling to⁣ collaborate, and vows to prevent pharmaceutical companies from ⁤”ripping off” patients ‍and taxpayers. He wants the NHS to benefit from and drive innovation in⁤ life sciences.
Industry‍ Position (ABPI): They argue the current scheme is unsustainable, hindering innovation and growth. They want a solution that improves patient access, allows for sector growth, and doesn’t require excessive revenue payback compared to other European countries. They warn of potential job and trial relocation⁢ if the situation doesn’t ‍improve.* Impact: This disagreement comes as the government launches a 10-year NHS plan and identifies life sciences as a key‍ industry for growth, creating a potential conflict between industrial strategy and healthcare cost control.